Effect of ipriflavone on bone mass in elderly osteoporotic women.
A study in elderly osteoporotic women was performed to assess the effect of one year treatment with ipriflavone (IP) on bone mass and bone biomarkers. Twenty-eight women aged over 65, with diagnosis of osteoporosis and X-ray evidence of at least one vertebral fracture, were treated with IP tablets (600 mg/day) or placebo (PL), according to a randomized, double-blind, parallel-group design. One g/day calcium supplementation was given to all patients. After 12 months a significant increase (+6%, P < 0.05) of bone mineral density (BMD) at the distal radius (DPA) was obtained in the IP-group. Serum osteocalcin (BGP) and urinary HO-proline/creatinine (HOP/Cr) values were reduced in the same group. BMD values did not change (-0.3%) in the placebo group. One woman of the PL-group was withdrawn from treatment because of worsening of pain, due to new vertebral crushes. Side effects (mainly gastrointestinal) arose in 8 IP- and in 5 PL-treated women. The compliance to the oral administration was good.
Passeri
M
M
Internal Medicine Institute, University of Parma, Italy.
Biondi
M
M
Costi
D
D
Bufalino
L
L
Castiglione
G N
GN
Di Peppe
C
C
Abate
G
G
D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density / Q000187:drug effects*; D003404:Creatinine / Q000652:urine; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007529:Isoflavones / Q000494:pharmacology / Q000627:therapeutic use*; D015675:Osteocalcin / Q000097:blood; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology; D016103:Spinal Fractures / Q000209:etiology
D007529:Isoflavones; D015675:Osteocalcin; C018986:ipriflavone; D003404:Creatinine; D006909:Hydroxyproline